EGFR and non-small cell lung carcinoma: Inhibition of HSF1 significantly overcomes resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which is the standard treatment for NSCLC patients with EGFR mutations, by downregulating the expression of HSPs [89].